Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02511106 · OUTCOME

Disease Free Survival (DFS) Rate at 2, 3 and 5 Years

AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy. · Source last updated 2026-03-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
Up to approximately 5 years after the first patient is randomized (maximum follow up of 70 months). DFS rate at 2 years (%), 3 years (%) and 5 years (%) are presented.

What was measured

Defined as the percentage of patients alive and disease free at 2, 3 and 5 years, respectively, estimated from Kaplan Meier plots of the primary endpoint of DFS.

Analysis population: Full analysis set (FAS) stage IIA-IIIA patients

Groups in this outcome

AZD9291 80mg Tablet

Taken once daily

Placebo Tablet

Taken once daily

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
AZD9291 80mg Tablet233
Placebo Tablet237

Reported measurements

DFS rate at 2 years (%)
Values in Percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
AZD9291 80mg Tablet90.0Not reported85.293.3Not reported
Placebo Tablet46.1Not reported39.652.4Not reported
DFS rate at 3 years (%)
Values in Percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
AZD9291 80mg Tablet83.5Not reported77.887.8Not reported
Placebo Tablet33.8Not reported27.840.0Not reported
DFS rate at 5 years (%)
Values in Percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
AZD9291 80mg Tablet53.0Not reported43.062.1Not reported
Placebo Tablet24.9Not reported19.031.2Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        85.2
        upper Limit
        93.3
        value
        90.0
      2. group Id
        OG001
        lower Limit
        39.6
        upper Limit
        52.4
        value
        46.1
    title
    DFS rate at 2 years (%)
  2. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        77.8
        upper Limit
        87.8
        value
        83.5
      2. group Id
        OG001
        lower Limit
        27.8
        upper Limit
        40.0
        value
        33.8
    title
    DFS rate at 3 years (%)
  3. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        43.0
        upper Limit
        62.1
        value
        53.0
      2. group Id
        OG001
        lower Limit
        19.0
        upper Limit
        31.2
        value
        24.9
    title
    DFS rate at 5 years (%)
denoms
  1. counts
    1. group Id
      OG000
      value
      233
    2. group Id
      OG001
      value
      237
    units
    Participants
description
Defined as the percentage of patients alive and disease free at 2, 3 and 5 years, respectively, estimated from Kaplan Meier plots of the primary endpoint of DFS.
dispersion Type
95% Confidence Interval
groups
  1. description
    Taken once daily
    id
    OG000
    title
    AZD9291 80mg Tablet
  2. description
    Taken once daily
    id
    OG001
    title
    Placebo Tablet
param Type
NUMBER
population Description
Full analysis set (FAS) stage IIA-IIIA patients
reporting Status
POSTED
time Frame
Up to approximately 5 years after the first patient is randomized (maximum follow up of 70 months). DFS rate at 2 years (%), 3 years (%) and 5 years (%) are presented.
title
Disease Free Survival (DFS) Rate at 2, 3 and 5 Years
type
SECONDARY
unit Of Measure
Percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice